Liver specialist Amit Singal joining U.K.’s Curve Therapeutics

BioCentury’s latest round of management updates for the biopharma sector includes the addition of Amit Singal to the team at Curve Therapeutics Ltd. Singal, who becomes CMO of the U.K. biotech, is chief of hepatology at UT Southwestern Medical Center and was the lead author of the most recent American Association for the Study of Liver Diseases Practice Guidance related to liver cirrhosis monitoring and management. Curve is a University of Southampton spinout that is taking on transcription factors and other intracellular targets that have eluded conventional discovery approaches, according to a recent BioCentury Emerging Company Profile of the company.

Alloy Therapeutics Inc. and DCx Biotherapeutics Corp. were among other biotechs adding to the C-suite. Alloy hired Alexander Titus as CEO, vigilance, to head its new vigilance unit focused on biosecurity and rapid therapeutic response. Titus is a commissioner on the U.S. National Security Commission on Emerging Biotechnology and was the first biotechnology strategy lead at the U.S. Department of Defense...